Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Intra-Cellular Therapies, Inc. (ITCI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
4
| VAN NOSTRAND ROBERT L (Director) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 105 shares
@ $52.09, valued at
$5.5k
|
|
| 10/02/2023 |
4
| RIGGS RORY B (Director) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 345 shares
@ $52.09, valued at
$18k
|
|
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/09/2023 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 55,300 shares
@ $58.79, valued at
$3.3M
Exercised 55,300 options to buy
@ $18.59, valued at
$1M
|
|
| 08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/07/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/07/2023 |
4/A
| Halstead Michael (EVP and General Counsel) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 40,472 options to buy
@ $53.63, valued at
$2.2M
|
|
| 07/07/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/05/2023 |
4
| RIGGS RORY B (Director) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 279 shares
@ $63.32, valued at
$17.7k
|
|
| 07/05/2023 |
4
| VAN NOSTRAND ROBERT L (Director) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 85 shares
@ $63.32, valued at
$5.4k
|
|
| 06/16/2023 |
4
| Hineline Lawrence J. (SVP of Finance CFO) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 34,227 shares
@ $63.35, valued at
$2.2M
Sold 44,035 shares
@ $64.37, valued at
$2.8M
Sold 3,592 shares
@ $65.01, valued at
$233.5k
Exercised 40,472 options to buy
@ $53.63, valued at
$2.2M
Exercised 25,082 options to buy
@ $23.94, valued at
$600.5k
Exercised 11,762 options to buy
@ $36.89, valued at
$433.9k
Exercised 4,538 options to buy
@ $56.73, valued at
$257.4k
|
|
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/04/2023 |
4
| VAN NOSTRAND ROBERT L (Director) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 95 shares
@ $54.15, valued at
$5.1k
|
|
| 04/04/2023 |
4
| RIGGS RORY B (Director) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 313 shares
@ $54.15, valued at
$16.9k
|
|
| 03/28/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
4
| Durgam Suresh K. (EVP, Chief Medical Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 6,998 shares
@ $45.08, valued at
$315.5k
Sold 346 shares
@ $44.29, valued at
$15.3k
Exercised 7,344 restricted stock units
@ $0 |
|
| 03/13/2023 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 16,708 shares
@ $0
Sold 6,750 shares
@ $43.5, valued at
$293.6k
Sold 1,800 shares
@ $42.74, valued at
$76.9k
Sold 3,335 shares
@ $45.1, valued at
$150.4k
Sold 423 shares
@ $44.05, valued at
$18.6k
Exercised 7,344 restricted stock units
@ $0 |
|
| 03/13/2023 |
4
| Halstead Michael (EVP and General Counsel) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 16,708 shares
@ $0
Sold 14,208 shares
@ $43.2, valued at
$613.8k
Sold 2,500 shares
@ $42.52, valued at
$106.3k
Sold 6,868 shares
@ $44.99, valued at
$309k
Sold 476 shares
@ $44.15, valued at
$21k
Exercised 7,344 restricted stock units
@ $0 |
|
| 03/13/2023 |
4
| Hineline Lawrence J. (SVP of Finance CFO) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 15,663 shares
@ $0
Sold 12,963 shares
@ $43.17, valued at
$559.6k
Sold 2,700 shares
@ $42.52, valued at
$114.8k
Sold 5,324 shares
@ $44.97, valued at
$239.4k
Sold 258 shares
@ $44.14, valued at
$11.4k
Exercised 5,582 restricted stock units
@ $0 |
|
| 03/13/2023 |
4
| Mates Sharon (Chairman, President & CEO) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 41,770 shares
@ $0
Sold 34,965 shares
@ $43.28, valued at
$1.5M
Sold 6,805 shares
@ $42.51, valued at
$289.3k
Sold 19,153 shares
@ $45.06, valued at
$863k
Sold 1,412 shares
@ $44.08, valued at
$62.2k
Exercised 20,565 restricted stock units
@ $0
Exercised 20,000 options to buy
@ $3.26, valued at
$65.2k
|
|
| 03/08/2023 |
4
| Durgam Suresh K. (EVP, Chief Medical Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 39,398 restricted stock units
@ $0 |
|
| 03/08/2023 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 39,398 restricted stock units
@ $0 |
|
| 03/08/2023 |
4
| Halstead Michael (EVP and General Counsel) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 39,398 restricted stock units
@ $0 |
|
| 03/08/2023 |
4
| Hineline Lawrence J. (SVP of Finance CFO) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 39,398 restricted stock units
@ $0 |
|
| 03/08/2023 |
4
| Mates Sharon (Chairman, President & CEO) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 122,137 restricted stock units
@ $0 |
|
|
|
|